Comparative models for any fragility fracture (hip, vertebral, or humeral) in male Veterans^*.

*Significant variables included in table. Other variables included in the model but not statistically significantly related to outcome: Pulmonary disease, peripheral vascular disease, major depressive disorder, coronary artery disease and/or diabetes mellitus, congestive heart failure, renal insufficiency, CD4 (per 100 cells/mm3), and tenofovir use. HIV-RNA was excluded from the model as it covaried with CD4 count (Pearson's R: 0.30) and only CD4 count was significantly associated with fragility fractures. **Hazard ratio (95% confidence interval). † Includes end stage liver disease, cirrhosis, chronic hepatitis B or C infection. ‡ TDF: tenofovir. ¥ PI: protease inhibitor.